Searching for 30mg Tirzepatide Peptide? Here's What the Dose Schedule Actually Looks Like

You found a "30mg tirzepatide peptide" listing and now you're not sure what you're looking at

That's an entirely understandable place to be. The terminology around tirzepatide online is genuinely confusing: licensed medicines, compounded formulations, and raw research peptides all share the same active ingredient name, and they circulate on the same search results page. A 30mg figure tends to appear in the context of "research peptide" suppliers, companies that sell tirzepatide as a laboratory compound, typically in vials, labelled "not for human use". These are not the same as the pre-filled Mounjaro KwikPen that a UK prescriber would authorise after a clinical assessment.

The distinction matters for your safety. Research-grade peptides are not subject to MHRA manufacturing standards, potency verification, or sterility testing for human administration. The MHRA has seized large quantities of fake and unverified weight-loss products circulating outside the licensed supply chain, some of which have caused harm. If you spotted a 30mg vial at a price that looked tempting, that context is worth sitting with for a moment before acting on it, and if you come across listings for even larger quantities, our page on 60 mg tirzepatide peptide explains what those products are and why the same concerns apply.

For factual background on what licensed tirzepatide actually involves, the NHS tirzepatide medicines page is a clear starting point.

What the licensed dose ladder from 2.5mg to 15mg actually covers

Licensed tirzepatide treatment in the UK starts at 2.5mg. That first pen exists to let your body adjust, nausea and other gastrointestinal effects are most common when the dose changes, and starting low reduces that considerably. From there, a prescriber typically steps the dose upward in four-weekly intervals: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg. The 5mg step is where many people begin to notice meaningful appetite changes; the higher steps build on that response.

Not everyone reaches 15mg. The prescriber's job is to find the dose that produces the best balance of effect and tolerability for you specifically. SURMOUNT-1, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at the 15mg level over 72 weeks, but that was an average across thousands of participants, each on an individually reviewed schedule. The trial also tested 5mg and 10mg, and both produced meaningful results. Titration is personal, not a race to the top.

If you're curious about what happens at the upper end of the schedule, the 15mg tirzepatide page covers that step in detail, including what the trial evidence shows and how a prescriber approaches that decision.

Why "peptide" products outside the licensed supply chain carry real risks

Tirzepatide is structurally a peptide (a chain of amino acids) and that is the technical reason research suppliers use the "peptide" label. But the word is doing a lot of work. A licensed Mounjaro pen contains a precisely formulated, sterility-tested, MHRA-approved medicine in a validated delivery device. A research vial contains a compound of uncertain concentration, prepared under conditions nobody has audited for pharmaceutical use.

The practical problems compound quickly. Without a known concentration you cannot calculate a dose accurately. Without a prescriber reviewing your health history, contraindications go unchecked, pancreatitis history, certain thyroid conditions, and interactions with other medicines all matter here. And without a licensed supply chain, you have no meaningful recourse if something goes wrong.

For anyone weighing up the cost side of things, the true cost of Mounjaro in the UK page sets out what legitimate private treatment actually costs and what those prices include, it is worth reading before drawing comparisons with unregulated vials.

The MHRA's Yellow Card reporting service exists partly for this reason: anyone who suspects they have purchased a counterfeit or substandard medicine can report it there, and doing so helps protect other people too.

What licensed treatment looks like if tirzepatide is something you want to explore properly

Mounjaro is licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under NICE guidance TA1026. A prescriber assesses the whole picture, not just a number on a scale, but your health history, current medicines, and whether this treatment is appropriate for you at all.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally and reaches a decision the same day. There is no algorithm making that call. The Mounjaro overview page covers the full picture of how the treatment works, what the evidence shows, and how the process runs from consultation through to delivery. How the dose is reviewed and adjusted over time is explained on the tirzepatide dosing guide, a useful read for anyone trying to understand what they are signing up for before they start.

If licensed treatment is something you want to discuss with a prescriber, you can start your free consultation at any time. There is no obligation, and the clinical team can answer questions that a web page cannot.